摘要 为了探讨肾移植后患者全血CsA谷浓度(TL)与临床的关系，寻求适合国人肾移植受者CsA理想治疗窗浓度范围。应用FPIA法特异性单克隆试剂盒测定口服CsA12小时后全血谷浓度。结果表明，肾移植后在应用标准三联免疫抑制治疗中，CsA理想治疗窗浓度范围应为：术后第1个月全血CsA-TL为350～450μg/L;第2个月为250～350μg/L；第3个月为250～300μg/L；第4个月以后CsA-TL应维持在150～250μg/L范围内。此浓度范围既能达到满意的免疫抑制效果，又能减少CsA的肝、肾毒性作用及排斥反应。因此，可视为国人肾移植受者CsA的理想治疗窗浓度范围。

    CsA therapeutic window concentration in renaltransplant recipients Zhu Youhua, MengGang, Min Zhilian, et al. Kidney Transplantation Center, Changzheng Hospital, the SecondMilitary Medical University, Shanghai 200003

    Abstract In renal transplant recipients on triple immunosuppressantsregimen, the CsA trough level 12 hours after its oral administration was assayed by meansof FPIA with the use of specific monoclone reagent kits. The ideal satisfactoryimmunosuppressive CsA trough levels were found as follows: The whole blood CsA troughlevel was 350～450μg/L within the first month after transplantation, 250～350μg/L in the second month,250～300 in the third month and within the range of150～250 since then. The aforementioned range oftherapeutic window concentration of CsA trough levels were claimed to be ideal for Chineserenal transplant recipients with no marked toxic effects to the liver and kidney.

     ......